Cel­lares rais­es $255M as it boosts its own man­u­fac­tur­ing ef­forts

Cel­lares, which is known for pro­duc­ing the tech­nol­o­gy used in cell ther­a­py man­u­fac­tur­ing, has raised $255 mil­lion in a Se­ries C as it aims to build out its own man­u­fac­tur­ing busi­ness.

The com­pa­ny’s think­ing is that con­tract man­u­fac­tur­ers are not cur­rent­ly able to meet glob­al de­mand, which has cre­at­ed a need for more CD­MOs with the tech­ni­cal know-how to man­u­fac­ture cell ther­a­pies, Cel­lares CEO Fabi­an Ger­ling­haus told End­points News.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.